Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 20;16(24):4244.
doi: 10.3390/cancers16244244.

Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study

Mellar P Davis  1 , Angela Ulrich  2 , Rebecca Segal  3 , Vinay Gudena  3 , Kathryn J Ruddy  4 , Stacy D'Andre  4 , Karthik V Giridhar  4 , Vamsi K Vasireddy  5 , Rajiv Agarwal  6 , Abdel-Ghani Azzouqa  7 , Paul Novotny  2 , Shaylene McCue  2 , Brent Bauer  8 , Charles L Loprinzi  4
Affiliations

Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study

Mellar P Davis et al. Cancers (Basel). .

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) from oxaliplatin and taxane drugs is a bothersome toxicity. Palmitoylethanolamide (PEA) has been reported to improve myelinated nerve fiber function in patients experiencing painful CIPN. We conducted a double-blind, placebo-controlled, randomized trial of PEA in patients with established CIPN. Methods: Eligible patients were adults who had pain, numbness, tingling, or other symptoms of CIPN for at least three months following completion of paclitaxel, oxaliplatin, or cisplatin-based chemotherapy. Study patients were randomized to one of the two treatment groups (PEA versus placebo, both administered either once or twice daily). The CIPN20 questionnaire was assessed weekly. Results: A total of 17 males and 71 females participated in the study; most had neuropathy from paclitaxel. Most (85%) finished 8 weeks of treatment. There was no suggestion that either of the PEA arms did any better than the combined placebo arms. There was no signal of significant toxicity differences between the three study arms. Quality of life outcome measures were similar between the study arms, as were cognitive function evaluations. Discussion: PEA failed to improve established CIPN. Future trials might explore whether PEA may be effective in preventing CIPN or cognitive changes based on data that suggest it may be helpful in this situation. Conclusions: PEA failed to improve established chemotherapy-induced neuropathy.

Keywords: chemotherapy-induced neuropathy; palmitoylethanolamide (PEA).

PubMed Disclaimer

Conflict of interest statement

The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Consort Diagram.
Figure 2
Figure 2
Percent of Baseline Scores from Baseline to Week 8 by Arm. Note that the placebo arm did numerically better than the two treatment arms, with a p-value of 0.11.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zhang J., Xu H.X., Wu Y.L., Cho W.C.S., Xian Y.F., Lin Z.X. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling. Adv. Biol. 2023;7:e2300062. doi: 10.1002/adbi.202300062. - DOI - PubMed
    1. Le D.T., Bui L.T., Nguyen C.V., Do K.H., Tran G.L., Do T.A. Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam. Oncol. Ther. 2023;11:327–341. doi: 10.1007/s40487-023-00233-8. - DOI - PMC - PubMed
    1. Nishihara-Kato F., Imai H., Tsuda T., Wasamoto S., Nagai Y., Kishikawa T., Miura Y., Ono A., Yamada Y., Masubuchi K., et al. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel. Oncology. 2023;102:30–42. doi: 10.1159/000533604. - DOI - PubMed
    1. Omori M., Minegishi Y., Uruga H., Fukuizumi A., Isobe K., Izumi S., Koyama R., Bando M., Sugiyama H., Takahashi K., et al. Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study. Respir. Investig. 2023;61:625–631. doi: 10.1016/j.resinv.2023.06.002. - DOI - PubMed
    1. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., Mannel R.S., DeGeest K., Hartenbach E.M., Baergen R. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2023;41:4077–4083. doi: 10.1200/JCO.22.02766. - DOI - PubMed

LinkOut - more resources